MacroGenics Revenue Doubles in Q2
(NASDAQ:MGNX), a biotechnology company focused on antibody-based cancer treatments, reported its second-quarter results on August 14, 2025. The release showed GAAP revenue of $22.2 million, which fell well below Wall Street's GAAP projection of $31.7 million. The loss per share (GAAP) was $(0.57), also missing the $(0.42) GAAP EPS expected by analysts. While GAAP revenue more than doubled from the prior-year quarter, the results disappointed due to the complete absence of product sales following the company’s exit from its previous marketed product. Management pointed to lower operating costs as a bright spot, but overall, the quarter reflected difficulties in offsetting lost product revenue and underlined the company’s ongoing strategic transition.
Source: Analyst estimates for the quarter provided by FactSet.
MacroGenics develops monoclonal antibodies and antibody-drug conjugates to treat various forms of cancer. The company builds its business model around advancing clinical candidates through to late-stage development, then partnering or out-licensing these assets to larger firms for commercialization, often in exchange for milestone payments and royalties.
Source Fool.com
MacroGenics Inc. Stock
Currently there is a rather positive sentiment for MacroGenics Inc. with 4 Buy predictions and 0 Sell predictions.
With a target price of 2 € there is a positive potential of 47.93% for MacroGenics Inc. compared to the current price of 1.35 €.
